Source: Annual Congress 2002 - Asthma - Therapy and management -1
Disease area: Airway diseases

Abstract

AIM(S): The Symbicort Adjustable Maintenance Plan is designed to gain and maintain optimal asthma control with a lower overall dose of budesonide/formoterol combination (B/F; Symbicort® Turbuhaler®) than fixed dosing. METHODS: Patients with mean overall quality of life (QoL; Mini Asthma Quality of Life Questionnaire) score of 4.6; activity score 5.2; symptom score 4.4; emotional score 4.3 and environment score 4.4 were randomised to the Adjustable Maintenance Plan (n=782; B/F 2 inhalations bid for 4 weeks, then 1–4 inhalations bid depending on asthma symptoms for 12 weeks; Group A) or fixed dosing (n=771; 2 inhalations bid for 16 weeks; Group B). RESULTS: Clinically relevant improvements in QoL occurred during the first 4 weeks (improvement >0.5 in all domains) in both groups. At week 4, in both groups, mean overall score was 5.4; activity score 5.8; symptom score 5.3, emotional score 5.2, environment score 5.1, and this was maintained throughout the following 12-week period. The average daily number of B/F inhalations per patient was 15% lower in Group A compared with Group B (3.2 vs. 3.8, respectively). CONCLUSIONS: Adjustable maintenance treatment with budesonide/formoterol was associated with similar rapid and sustained QoL improvements to fixed dosing with a lower overall daily dose.

Rating:

Share or cite this content

Citations should be made in the following way:
J. Haughney, D. Price, J. P. Rosen, J. Kennelly (Aberdeen, Luton, United Kingdom). Adjustable maintenance treatment with budesonide/formoterol combination rapidly improves and maintains quality of life in asthma patients. Eur Respir J 2002; 20: Suppl. 38, 379

Member's Comments

No comment yet.

Related content which might interest you: Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life Source: Eur Respir J 2003; 22: Suppl. 45, 51s Year: 2003 Adjustable dosing with budesonide/formoterol in a single inhaler maintains improvement in health-related quality of life at a lower drug load than fixed dosing – the ATACO study Source: Eur Respir J 2003; 22: Suppl. 45, 258s Year: 2003 Stability of overall asthma control achieved with budesonide/formoterol maintenance + reliever therapy Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009 Budesonide/formoterol maintenance and reliever therapy compared to conventional best practice in the treatment of persistent asthma Source: Eur Respir J 2007; 30: Suppl. 51, 616s Year: 2007 Formoterol Turbuhaler® reduces the need for relief medication in children with mild to moderate asthma and improves quality of life Source: Eur Respir J 2001; 18: Suppl. 33, 291s Year: 2001 Variation of regular maintenance therapy with budesonide/formoterol of children with asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008 Adding omalizumab to high-dose ICS and LABA significantly improves quality of life in patients with severe persistent allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006 Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Budesonide/formoterol adjustable maintenance dosing effectively improves asthma symptom severity: a multicentre Canadian study Source: Eur Respir J 2003; 22: Suppl. 45, 258s Year: 2003 Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 Tiotropium reduces oral prednisone requirements while improving respiratory function in patients with severe persistent asthma Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016 Tiotropium + olodaterol fixed-dose combination shows clinically meaningful improvements in quality of life versus placebo Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Budesonide/formoterol maintenance and reliever therapy use in elderly asthma patients Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with fixed dosing – 3-month study Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017 Adjustable maintenance dosing with budesonide/formoterol controls asthma symptom severity and maintains lung function with a lower overall dose than fixed dosing: results of an Italian study Source: Eur Respir J 2003; 22: Suppl. 45, 259s Year: 2003 4-month adjustable or fixed maintenance treatment with budesonide/formoterol in a single inhaler reduces symptom severity Source: Eur Respir J 2002; 20: Suppl. 38, 41s Year: 2002 Adjustable dosing with budesonide/formoterol achieves sustained guideline ‘well-controlled asthma‘ following step down in treatment Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005 The influence of fenspiride in complex therapy on quality of life in COPD patients Source: Annual Congress 2010 - COPD: management Year: 2010 Overall asthma control with budesonide/formoterol maintenance and relief vs conventional best practice Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease Source: Eur Respir J 2003 Dec 01;22(6):912-919 Year: 2003